Close Menu

Regulus

Regulus Therapeutics this week announced that it has selected its first drug candidate, RG-101 for the treatment of hepatitis C. However, the company said it will develop the compound on its own despite an ongoing collaboration on the disease with GlaxoSmithKline.

Privately held transdermal drug delivery firm Zosano Pharma said it has appointed Kleanthis Xanthopoulos to its board of directors.

Regulus Therapeutics has named William Rastetter as a member of its board.

Officials from Regulus Therapeutics this week said that the company continues to plan on filing two investigational new drug applications in 2014, one of which is for a microRNA-122-targeting hepatitis C treatment, but fell short of promising the goal would be met.

Santaris Pharma this week announced that the US Patent and Trademark Office has accepted its request to re-examine a patent exclusively licensed by rival Regulus Therapeutics covering the use of microRNA-122 inhibitors to treat hepatitis C infection.

Though not as advanced a therapeutic technology as its RNAi cousin, microRNA received a lot of positive attention from the investment community in 2012, with the top companies in the space pulling in nearly $150 million in financing dollars over the past year.

Researchers from the University of North Carolina this week published new data on the role of microRNA-122 in hepatitis C infection, detailing the specific degradation pathways against which the miRNA protects the virus.

The management of Regulus Therapeutics last week provided a few new details on the company's pipeline, promising that it would have two microRNA drug candidates ready for clinical trials before the end of next year.

Regulus Therapeutics has named Victor Knopov its vice president of pharmaceutical development.

Regulus Therapeutics this week announced that it grossed a total of $80.9 million from its recent initial public offering on the Nasdaq and other transactions.

Pages

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.